Trade

with

Pharmacyclics Inc
(NASDAQ: PCYC)
AdChoices
123.68
+2.36
+1.95%
After Hours :
123.68
0.00
0.00%

Open

121.91

Previous Close

121.32

Volume (Avg)

715.59k (899.30k)

Day's Range

120.53-124.19

52Wk Range

82.51-154.89

Market Cap.

9.31B

Dividend Rate ( Yield )

-

Beta

0.67

Shares Outstanding

75.27M

P/E Ratio (EPS)

111.11 (1.12)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 260.17M

    • Net Income

    • 67.01M

    • Market Cap.

    • 9.31B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 20.18

    • PEG (Price/Earnings Growth) Ratio

    • 4.58

    • Beta

    • 0.67

    • Forward P/E

    • 178.57

    • Price/Sales

    • 22.32

    • Price/Book Value

    • 14.27

    • Price/Cash flow

    • 64.52

      • EBITDA

      • 100.14M

      • Return on Capital %

      • 12.57

      • Return on Equity %

      • 15.75

      • Return on Assets %

      • 12.57

      • Book Value/Share

      • 8.67

      • Shares Outstanding

      • 75.27M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 183.25

        • Credit Rating

        • -

        • Analysts

        • 6

        • EPS Estimate

        • 0.20

        • Cashflow Estimate

        • 0.31

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 106.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 214.00

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 78.38

            • 82.75

            • Pre-Tax Margin

            • 27.59

            • 39.38

            • Net Profit Margin

            • 20.18

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 6.03

              • 2.92

              • Quick Ratio

              • 5.59

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.27

              • 2.21

              • Book Value/Share

              • 8.67

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 111.11

                • 217.39

                • P/E Ratio 5-Year High

                • 138.65

                • 634.30

                • P/E Ratio 5-Year Low

                • 1.53

                • 124.82

                • Price/Sales Ratio

                • 22.32

                • 9.52

                • Price/Book Value

                • 14.27

                • 8.61

                • Price/Cash Flow Ratio

                • 64.52

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 15.75

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 12.57

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 15.75

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 181.38k

                  • 117.08k

                  • Inventory Turnover

                  • 2.46

                  • 1.48

                  • Asset Turnover

                  • 0.62

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  97.92M
                  Operating Margin
                  37.64
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  64.52
                  Ownership

                  Institutional Ownership

                  75.83%

                  Top 10 Institutions

                  51.94%

                  Mutual Fund Ownership

                  42.46%

                  Float

                  59.32%

                  5% / Insider Ownership

                  20.08%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Health Sciences Fund

                  •  

                    2,029,400

                  • 7.63

                  • 2.70

                  • Columbia Select Large Cap Growth Fund

                  •  

                    1,876,529

                  • 0.00

                  • 2.49

                  • T. Rowe Price Growth Stock Fund

                  •  

                    1,488,000

                  • 15.26

                  • 1.98

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    1,451,922

                  • 0.00

                  • 1.93

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    1,352,339

                  • -1.54

                  • 1.80

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,129,313

                  • 0.00

                  • 1.50

                  • Vanguard Mid-Cap Index Fund

                  •  

                    1,032,615

                  • 1.68

                  • 1.37

                  • Vanguard Total Stock Mkt Idx

                  •  

                    982,448

                  • 1.04

                  • 1.31

                  • T. Rowe Price New Horizons Fund

                  •  

                    832,500

                  • 9.41

                  • 1.11

                  • Bb Biotech AG

                  •  

                    731,542

                  • 0.00

                  • 0.97

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    9,591,546

                  • +9.77%

                  • 12.74

                  • T. Rowe Price Associates, Inc.

                  •  

                    7,751,307

                  • +15.64%

                  • 10.30

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    4,257,195

                  • +23.48%

                  • 5.66

                  • Vanguard Group, Inc.

                  •  

                    3,473,563

                  • +2.14%

                  • 4.62

                  • Janus Capital Management LLC

                  •  

                    3,211,372

                  • +303.32%

                  • 4.26

                  • Capital World Investors

                  •  

                    2,976,977

                  • +110.49%

                  • 3.96

                  • PRIMECAP Management Company

                  •  

                    2,313,039

                  • -2.84%

                  • 3.07

                  • Fidelity Management and Research Company

                  •  

                    2,254,243

                  • -4.71%

                  • 3.00

                  • BlackRock Fund Advisors

                  •  

                    1,782,257

                  • +1.27%

                  • 2.37

                  • Fred Alger Management, Inc.

                  •  

                    1,477,603

                  • +0.87%

                  • 1.96

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Pharmacyclics Inc was incorporated in Delaware in 1991 and commenced operations in 1992. It is a biopharmaceutical company designing, developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated...more diseases. On November 13, 2013, the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib, PCI-32765) as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and concurrently on November 13, 2013, the Company commercially launched IMBRUVICATM in the United States. The Company’s competitors include major pharmaceutical and biotechnology companies, clinical reference laboratories and government agencies, as well as academic research institutions that are pursuing research activities simila...morer to the company. The Company has contracted with a third-party logistics company to warehouse IMBRUVICATM and distribute it to wholesalers, distributors, pharmacies, hospitals, and other drug suppliers that ultimately distribute IMBRUVICATM directly to patients. The FDA and applicable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.lessless

                  Key People

                  Robert W. Duggan

                  Director/CEO/Chairman of the Board

                  Manmeet Singh Soni

                  CFO/Chief Accounting Officer/Executive VP, Divisional/Treasurer

                  Dr. David J. Loury,PhD

                  Executive VP, Divisional

                  Dr. Joseph J. Buggy,PhD

                  Vice President, Divisional

                  Richard B. Love

                  General Counsel/Secretary/Vice President

                  • Pharmacyclics Inc

                  • 995 East Arques Avenue

                  • Sunnyvale, CA 94085-4521

                  • USA.Map

                  • Phone: +1 408 774-0330

                  • Fax: +1 408 774-0340

                  • pharmacyclics.com

                  Incorporated

                  1991

                  Employees

                  484

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: